Am J Transl Res

1. GOTO T, Akai T, Teramoto Y, Miyamoto H, et al
   Latrophilin-1 and latrophilin-2 as androgen receptor-responsive G protein-coupled receptors promote bladder cancer progression.
   Am J Transl Res. 2025;17:6403-6413.
   

   >> Share

   
   
2. SHAO Y, Guan Y, Zhao J, Abudurexiti M, et al
   Alternating intravesical instillation of Bacillus Calmette-Guerin and Pseudomonas aeruginosa effectively prevents postoperative recurrence in high-risk non-muscle-invasive bladder cancer.
   Am J Transl Res. 2025;17:6619-6629.
   

   >> Share

   
   

   
   Arch Ital Urol Androl

3. LOPES M, Pereira J, Temido MJ, Gama J, et al
   Prognostic value of combined tumor regression grade and TNM stage in muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy.
   Arch Ital Urol Androl. 2025 Sep 17:14264. doi: 10.4081/aiua.2025.14264.
   

   >> Share

   
   

   
   BJUI Compass

4. HIONG A, Lynam J, Weickhardt A, Wong S, et al
   Perioperative chemotherapy use and related outcomes in muscle-invasive bladder cancer in Australia.
   BJUI Compass. 2025;6:e70083.
   

   >> Share

   
   

   
   Cancer Med

5. ISHII N, Sekine Y, Shinohara M, Kawashima Y, et al
   Effects of Avelumab Maintenance on Advanced Urothelial Carcinoma: A Real-World Multicenter Study.
   Cancer Med. 2025;14:e71241.
   

   >> Share

   
   
6. HUANG X, Wang X, He Z, Huang Y, et al
   Mechanisms, Clinical Trials, and New Treatments for BCG-Unresponsive in Nonmuscle Invasive Bladder Cancer.
   Cancer Med. 2025;14:e71243.
   

   >> Share

   
   

   
   Cancer Rep (Hoboken)

7. URUSHIBARA M, Kato D, Okumura T, Kojima A, et al
   Long-Term Survival Obtained by Repeated Cytoreductive Surgery and S-1 Plus Cisplatin Chemotherapy at Each Instance of Disease Progression in a Patient With Metastatic Urachal Carcinoma: A Case Report.
   Cancer Rep (Hoboken). 2025;8:e70317.
   

   >> Share

   
   

   
   Cancers (Basel)

8. DEVAR J, Elebo N, Makan A, Pincus A, et al
   Distinct Metabolomic and Lipoprotein Signatures in Gall Bladder Cancer Patients of Black African Ancestry.
   Cancers (Basel). 2025;17:2925.
   

   >> Share

   
   
9. SETTI BOUBAKER N, Gurtner A, Boussetta S, Manni I, et al
   Dysregulated MicroRNAs in Urinary Non-Muscle-Invasive Bladder Cancer: From Molecular Characterization to Clinical Applicability.
   Cancers (Basel). 2025;17:2768.
   

   >> Share

   
   

   
   Chembiochem

10. GRIMMEISEN M, Wang X, Weldle M, Sartory K, et al
    Synthesis and Evaluation of Trehalose-Based Mertansine Warheads for Bacillus Calmette-Guerin Delivery of Anticancer Agents.
    Chembiochem. 2025;26:e202500390.
    

    >> Share

    
    

    
    Chin Med J (Engl)

11. WANG J, Yang J, Yao K, Tan J, et al
    m6A-modified circCD2AP suppressed ferroptosis in bladder cancer by upregulating FOXC1 to promote PARK7 transcriptional activity.
    Chin Med J (Engl). 2025 Sep 16. doi: 10.1097/CM9.0000000000003744.
    

    >> Share

    
    

    
    Clin Cancer Res

12. STOCKEM CF, Gil-Jimenez A, Ali H, van Dorp J, et al
    Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study.
    Clin Cancer Res. 2025;31:3897-3906.
    

    >> Share

    
    

    
    Clin Genitourin Cancer

13. HAN T, Cui H, Du G, Guan Y, et al
    Expression and Prognostic Significance of Different Antibody-Drug Conjugate Target Proteins in Urachal Carcinoma.
    Clin Genitourin Cancer. 2025;23:102403.
    

    >> Share

    
    
14. HAN W, Yu X, Chen S, Ou Z, et al
    Clinical Characteristics and Surgical Outcomes of Bladder Paraganglioma: A 20-Year Nationwide Center Experience.
    Clin Genitourin Cancer. 2025;23:102397.
    

    >> Share

    
    
15. SLUSARCZYK A, Scilipoti P, Contieri R, Longoni M, et al
    Comparative Assessment of Chemotherapy Followed by Consolidative Radical Cystectomy Versus Chemoradiation for Clinically Node-Positive Urothelial Carcinoma of the Bladder.
    Clin Genitourin Cancer. 2025;23:102399.
    

    >> Share

    
    

    
    Cureus

16. IBRAHEEM N, Abosheisha M, Alemam A, Abbas M, et al
    Integrated Magnetic Resonance Imaging in Muscle-Invasive Bladder Cancer: A Comprehensive Review.
    Cureus. 2025;17:e90077.
    

    >> Share

    
    
17. SHEBANI MAA, Ikdees AA, Alazeebi SY, Nagib E, et al
    A Multifactorial Case of Retroperitoneal Fibrosis in a Post-radiation Bladder Cancer Patient: Diagnostic and Therapeutic Challenges.
    Cureus. 2025;17:e89976.
    

    >> Share

    
    

    
    Curr Opin Urol

18. OUALLA K, Alem M, Teoh J
    Systemic immunotherapy for BCG unresponsive nonmuscle-invasive bladder cancer.
    Curr Opin Urol. 2025 Sep 15. doi: 10.1097/MOU.0000000000001334.
    

    >> Share

    
    

    
    Front Immunol

19. LANG Y, Li P, He R, Zhu B, et al
    Dynamic changes of urinary microbiota in patients with bladder cancer after surgery and its clinical significance.
    Front Immunol. 2025;16:1638628.
    

    >> Share

    
    
20. CAO J, Zheng W
    Angiogenesis-related gene NID2 profiling and immune infiltration in bladder cancer: prognostic implications and immunotherapy response.
    Front Immunol. 2025;16:1615173.
    

    >> Share

    
    

    
    Histol Histopathol

21. OHMOTO A, Kitahama K, Shigematsu Y, Hayashi N, et al
    Genomic features of bladder neuroendocrine carcinoma with composite histology.
    Histol Histopathol. 2025;40:1547-1554.
    

    >> Share

    
    

    
    Int Braz J Urol

22. SIMOES GCS, Calderon J, Claros OR, Alfer W, et al
    Robotic Partial Cystectomy for Urachal Adenocarcinoma: Surgical Technique with Cys-toscopic Correlation.
    Int Braz J Urol. 2026;52:e20250446.
    

    >> Share

    
    

    
    Int Immunopharmacol

23. MA B, Ma C, Long X, Jiang L, et al
    Stromal reprogramming in urachal cancer: Fibroblast activation protein and collagen remodeling drive immune-suppressive niches and immunotherapy resistance.
    Int Immunopharmacol. 2025;163:115204.
    

    >> Share

    
    

    
    Int J Biol Sci

24. HAN Y, Li C, Wu G
    Comment on "IGF2BP3 promotes the proliferation and cisplatin resistance of bladder cancer by enhancing the mRNA stability of CDK6 in an m(6)A dependent manner".
    Int J Biol Sci. 2025;21:5284-5286.
    

    >> Share

    
    

    
    Int J Med Sci

25. CHEN H, Ma L, Ji Z, Dong J, et al
    FAM174B remodels the tumor microenvironment, inhibits the infiltration of macrophage, predicts the molecular subtype and therapeutic response of bladder cancer.
    Int J Med Sci. 2025;22:3737-3748.
    

    >> Share

    
    

    
    Int J Mol Sci

26. DAVIDSSON S, Jerlstrom T, Carlsson J
    Optimizing Tissue Sampling Timing for Accurate Gene Expression Analysis.
    Int J Mol Sci. 2025;26:8581.
    

    >> Share

    
    

    
    Int J Surg

27. LIU L, Li JP, Gao LX, An L, et al
    Risk factors for acute kidney injury following radical cystectomy: a systematic review and meta-analysis.
    Int J Surg. 2025;111:6330-6342.
    

    >> Share

    
    
28. LIU L, He LY, Zhang PY, Xiao Y, et al
    Neuroendocrine carcinoma of the bladder: do they have a worse prognosis? A large retrospective cohort study by propensity score matching analysis.
    Int J Surg. 2025;111:6435-6440.
    

    >> Share

    
    

    
    J Immunother Cancer

29. HABAZ IA, Ou X, Wang NI, Schincaglia A, et al
    MAIT cells promote cancer progression and regulatory T cell accumulation in bladder tumor microenvironment.
    J Immunother Cancer. 2025;13:e012496.
    

    >> Share

    
    

    
    J Manag Care Spec Pharm

30. SQUIRES P, Cook EE, Song Y, Wang CY, et al
    Real-world economic burden of disease recurrence in patients with muscle-invasive bladder cancer: A population-level claims-based analysis.
    J Manag Care Spec Pharm. 2025 Sep 17:1-11. doi: 10.18553/jmcp.2025.25106.
    

    >> Share

    
    

    
    J Pathol

31. YANG T, Sun X, Chen J, Li J, et al
    MS4A4A-positive tumor-associated macrophages associate with poor prognosis and T-cell exhaustion in patients with urothelial carcinoma of the bladder.
    J Pathol. 2025;267:225-239.
    

    >> Share

    
    

    
    J Racial Ethn Health Disparities

32. DE ANGELIS M, Jannello LMI, Siech C, Di Bello F, et al
    Race/Ethnicity Affects Access and Survival Differences After Neoadjuvant or Adjuvant Chemotherapy at Radical Cystectomy in Urothelial Carcinoma Patients.
    J Racial Ethn Health Disparities. 2025;12:3284-3293.
    

    >> Share

    
    

    
    J Robot Surg

33. PARK IW, Noh TI, Kang SH, Oh JJ, et al
    Demonstrating the non-inferiority of robotic radical cystectomy for cT3-cT4 urothelial carcinoma in the era of neoadjuvant chemotherapy: a propensity score-matched analysis.
    J Robot Surg. 2025;19:596.
    

    >> Share

    
    

    
    JCO Precis Oncol

34. GUPTA S, Lee JK, Mitchell J, Huang RSP, et al
    Fibroblast Growth Factor Receptor 3 Alteration Status and Outcomes on Immune Checkpoint Inhibitors in Patients With Metastatic Urothelial Carcinoma.
    JCO Precis Oncol. 2025;9:e2500257.
    

    >> Share

    
    

    
    Medicine (Baltimore)

35. LIU Z, Tu J, Long J, Guo L, et al
    Causal relationships between immune cells and common urinary system tumors: A bidirectional analysis of Mendelian randomization.
    Medicine (Baltimore). 2025;104:e44297.
    

    >> Share

    
    
36. LIU Y, Li J, Liang G, Fang F, et al
    The mediating effect of dyadic coping between illness perception and fear of disease progression in bladder cancer patients: A cross-sectional survey.
    Medicine (Baltimore). 2025;104:e44520.
    

    >> Share

    
    

    
    Nat Med

37. GALSKY MD, Bajorin DF, Tomita Y, Ye D, et al
    Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial.
    Nat Med. 2025;31:3062-3073.
    

    >> Share

    
    

    
    Oncogene

38. XIE J, Zhang H, Wang K, Ni J, et al
    Correction: M6A-mediated-upregulation of lncRNA BLACAT3 promotes bladder cancer angiogenesis and hematogenous metastasis through YBX3 nuclear shuttling and enhancing NCF2 transcription.
    Oncogene. 2025 Sep 17. doi: 10.1038/s41388-025-03575.
    

    >> Share

    
    

    
    Pathol Res Pract

39. KHANI F, Beg S, Park K, Kawaguchi K, et al
    SPINK1 immunohistochemistry: An ancillary tool to diagnose urothelial carcinoma in situ and urothelial dysplasia.
    Pathol Res Pract. 2025;273:156148.
    

    >> Share

    
    

    
    Radiol Oncol

40. MARKOVIC G, Resnik N, Janev A, Zupancic D, et al
    The role of focal adhesion kinase in bladder cancer: translation from in vitro to ex vivo human urothelial carcinomas.
    Radiol Oncol. 2025;59:349-367.
    

    >> Share

    
    

    
    Transl Androl Urol

41. HASHIMOTO M, Fukiage K, Taniguchi K, Minami T, et al
    Upper urinary tract urothelial carcinoma patients show better overall response rate than bladder cancer patients during enfortumab vedotin treatment following pembrolizumab.
    Transl Androl Urol. 2025;14:2279-2288.
    

    >> Share

    
    

    
    Transl Oncol

42. TIAN S, Wang C, Zhao X, Xuan Y, et al
    A CEBPB/TYMP/GDF15 signaling axis mediates tumor growth and cisplatin resistance in bladder cancer.
    Transl Oncol. 2025;61:102537.
    

    >> Share

    
    
43. LAI Y, Peng Z, He Z, Lu Z, et al
    Dioscin initiates dual roles in bladder cancer progression via miR-195-5p/FASN/SLC3A2 axis-mediated cell death mechanisms.
    Transl Oncol. 2025;61:102534.
    

    >> Share

    
    

    
    World J Urol

44. WILLIAMS C, Talwar R, Ramchandani P, Smith AL, et al
    Characterizing pelvic organ descent in women after radical cystectomy: an exploratory analysis.
    World J Urol. 2025;43:559.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share